Balaji Amines Ltd. shares achieved their fresh 52-week high on Tuesday, June 2, 2026, with the stock gaining 19% in a single session. According to Business Standard, the stock price hit a 52-week high of ₹2,062.50, surpassing its previous high of ₹1,956.80 touched on May 25, 2026. The stock is currently trading 17% higher at ₹2,027.50 and has emerged as the top gainer on the BSE Smallcap index. The stock has demonstrated exceptional momentum, with past three weeks seeing a 54% surge and past three months delivering a remarkable 128% gain, significantly outperforming the BSE Sensex's near 7% decline during the same period.
The stock witnessed unprecedented trading volumes with average trading volumes jumping over six-fold, with a combined 2.25 million shares changing hands on NSE and BSE. As reported by Business Standard, 17% of the shares traded are marked for delivery, indicating strong investor interest. The sharp spike in volumes post 12.45 PM on Tuesday demonstrates the intensity of the buying interest in the stock. The trading activity reflects significant institutional and retail participation in the specialty chemicals stock.
The company reported robust fourth quarter results for Q4FY26, with revenue from operations standing at ₹403 crore compared to ₹361 crore in Q3FY26, indicating stable operational performance around 12% growth. According to Business Standard, EBITDA margin improved significantly to 25% in Q4FY26 as against 18% in Q3FY26 and 19% in Q4FY25, supported by better operating leverage, stable raw material conditions, prudent inventory planning, improved cost efficiencies and favorable product mix. The company's profit after tax more than doubled to ₹65 crore compared to ₹31 crore in Q3FY26. The performance was supported by stable demand across key segments and improved cost absorption from the integrated manufacturing model.
As reported by Business Standard, Balaji Amines remains well positioned for gradual ramping up of operations, backed by a resilient business plan and growing specialty chemicals portfolio. The company enjoys leadership positions in many products including Monomethylamine (MMA), Dimethyl amine (DMA), Trimethylamine (TMA), and Dimethyl Amino Ethanol (DMAE). The commissioning of DME, N-Methyl Morpholine (NMM), Acetonitrile and expansion projects of Balaji Specialty Chemicals will be important milestones over the coming quarters. While management remains watchful of raw material prices, global demand conditions and geopolitical developments, they believe the company is well placed for gradual growth.
